Hans D. Menssen

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 841 citations · Full text

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus, Tamás Masszi, Francis J. Giles et al. · Leukemia · 2017 · 286 citations · Full text

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Timothy P. Hughes, Giuseppe Saglio, Hagop M. Kantarjian et al. · Blood · 2013 · 251 citations

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano et al. · European Journal of Cancer · 2010 · 179 citations

Urology, Cancer Immunosurveillance, Genitourinary Cancer +7